Raymond James Financial Inc. Takes Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Raymond James Financial Inc. acquired a new position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 1,765,593 shares of the company's stock, valued at approximately $38,914,000. Raymond James Financial Inc. owned about 0.16% of Teva Pharmaceutical Industries at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in TEVA. Stifel Financial Corp lifted its position in shares of Teva Pharmaceutical Industries by 54.0% during the third quarter. Stifel Financial Corp now owns 66,391 shares of the company's stock valued at $1,196,000 after purchasing an additional 23,283 shares in the last quarter. Robeco Institutional Asset Management B.V. lifted its position in shares of Teva Pharmaceutical Industries by 7.2% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 498,309 shares of the company's stock worth $10,983,000 after buying an additional 33,277 shares in the last quarter. Pinnbrook Capital Management LP purchased a new position in shares of Teva Pharmaceutical Industries in the 4th quarter worth approximately $4,966,000. Asset Management One Co. Ltd. grew its holdings in shares of Teva Pharmaceutical Industries by 14.6% in the fourth quarter. Asset Management One Co. Ltd. now owns 457,371 shares of the company's stock valued at $10,414,000 after acquiring an additional 58,413 shares in the last quarter. Finally, CWA Asset Management Group LLC purchased a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter valued at approximately $3,340,000. Institutional investors own 54.05% of the company's stock.

Teva Pharmaceutical Industries Stock Performance

Shares of Teva Pharmaceutical Industries stock traded down $0.48 during trading hours on Monday, reaching $13.18. The company had a trading volume of 2,071,098 shares, compared to its average volume of 9,873,362. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. Teva Pharmaceutical Industries Limited has a one year low of $12.47 and a one year high of $22.80. The firm has a market cap of $14.94 billion, a PE ratio of -9.04, a price-to-earnings-growth ratio of 1.44 and a beta of 0.72. The business has a fifty day simple moving average of $15.45 and a 200 day simple moving average of $17.67.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. On average, analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Analysts Set New Price Targets

TEVA has been the subject of several research analyst reports. UBS Group decreased their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research report on Thursday, January 30th. Bank of America dropped their target price on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a research note on Thursday, March 6th. Piper Sandler lifted their price target on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a report on Friday, January 17th. Barclays reduced their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a report on Thursday, January 30th. Finally, StockNews.com cut Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a research report on Monday, April 14th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. According to MarketBeat.com, Teva Pharmaceutical Industries has an average rating of "Moderate Buy" and an average price target of $23.43.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.